Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQX: LDSYF), (Frankfurt: LD6, WKN: A14XHT) (“LDS” or the “Company”) announces CSPA Group Inc. and LDS Scientific’s debut of CannaStripsTM and the Rêveur luxury brand of cannabis products for the California market during the Indio, CA desert festival weekends, which will take place on April 13-15, April 20-22 and April 27-29, 2018.
The products will be available from local delivery services and information on the products will be available at the CannaStripsTM/Rêveur promotion suite during all of the April 2018 Indio, CA desert festivals at the Base Camp enclave poolside, where exclusive special promotional coupons will be available.
CSPA Group Inc. has been test marketing five new 10-mg formula versions of CannaStripsTM. The following versions were used in the test marketing:
- 10 mg THC full spectrum strip with trace amounts of CBD and CBN;
- 5 mg THC and 5 mg CBD 50/50 blend;
- 8 mg CBD and 2 mg THC;
- the sleep version with 8 mg CBD, 2 mg THC, melatonin and serotonin; and
- 8 mg CBD 2 mg THCa, 10 mg curcumin with trace amounts of CBN and CBG.
The CEO of LDS, Brad Eckenweiler, commented, “These five versions represent the results of our market research combined with customer comments, requests and suggestions received over the past three months. The resulting products, we believe, represent the best combinations of ingredients to meet the demands of the current market given the regulatory guidelines.” The Company’s latest packaging and logo designs for CannaStripsTM and Rêveur will be posted on Reveurbrands.com, Cannastrips.com and LifestyleDeliverySystems.com, as early as on Tuesday, April 10, 2018.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…